Clinical trial
An Open-label Extension Study of Subcutaneously Administered Fitusiran in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With Fitusiran
NCT02554773 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study of Subcutaneously Administered Fitusiran in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With Fitusiran
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 18, 2015
- Completion date
- March 21, 2023
- Enrollment
- 34 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.